Anavex Life Sciences Corp (AVXL)

[growingpain]

First post here, but have been following for a few months. IMO, there is nothing surprising with price action over the past 3-4 weeks. The market has been valuing the stock at around $17-$18/share in September-October in the lack of any P3 data. Based on the clinicaltrials.gov page for AVATAR, this was still recruiting in August. This means that any topline data would not come before mid to end of Q4. In anticipation of this readout (the rest of the 2021H2 catalysts can offer minimum added value at this point IMO), the market started accumulating and FOMOing from the end of October until Wednesday last week when Missling announced the EC in the AM on Thanksgiving eve. This was perceived by the market as bad news. Some of my friends holding the stock immediately reduced their position then, some others waited until yesterday, just in case there is a PR, but since there was not one, we saw the big drop back to $17s. Bad move from Missling, unless there is indeed some negative news that could cause a market overreaction. We could still get “absolutely great news” in the morning, but if this does not happen and there is something negative to report during the EC, I hope this could be just a delay of the expected catalysts to 2022H1. Worst case scenario is mixed data from AVATAR. Just my two cents.